Skip to content

Evaluation of Intercostal Neuralgia in Patients With Chest Tube Insertion After Traumatic Rib Fracture

Prospective Evaluation of Intercostal Neuralgia Incidence, Risk Factors, and Outcomes in Patients With Chest Tube Insertion After Traumatic Rib Fractures

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07308587
Enrollment
100
Registered
2025-12-29
Start date
2026-01-19
Completion date
2027-12-31
Last updated
2026-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intercostal Nerve Injury

Brief summary

Traumatic rib fractures are common injuries following blunt chest trauma, often requiring chest tube insertion to manage complications such as pneumothorax or haemothorax. However, chest tube placement can lead to intercostal nerve injury, resulting in intercostal neuralgia-a debilitating condition characterized by chronic, neuropathic pain along the intercostal nerves. Despite its clinical significance, the incidence, risk factors, and long-term outcomes of intercostal neuralgia in this patient population remain poorly understood. Chronic pain following thoracic trauma, including intercostal neuralgia, has been shown to significantly impair quality of life and functional outcomes, leading to prolonged disability and increased healthcare utilization. Current literature highlights the need for better understanding and management of this condition, particularly in patients undergoing invasive procedures such as chest tube insertion. This study aims to prospectively evaluate the development of intercostal neuralgia in patients with chest tube insertion following traumatic rib fractures.

Detailed description

Intercostal neuralgia is defined as pain along the intercostal nerve distribution with neuropathic features. Chronic intercostal neuralgia is defined as having intercostal neuralgia symptoms for \>3 months. Intercostal neuralgia pain will be specifically differentiated from persistent rib fracture pain through the presence of neuropathic pain at the level of the chest tube/pigtail that is reproducible with brushing/light touch to the chest tube scar site. The following data will be collected: Baseline: * Demographic information (age, sex, ethnicity, comorbidities). * Pain assessment using numerical rating scale at rest and with deep inspiration * Pre-existing chronic pain conditions (e.g., fibromyalgia, chronic regional pain syndrome) and history of prior thoracic surgery or chest tube insertion. * Injury characteristics (mechanism of injury including presence of foreign bodies and additional penetrating injuries, number and location of rib fractures, associated injuries including vertebral body fractures, sternal fracture, transverse process fracture). * Neurologic assessment (Glasgow Coma Scale \[GCS\] on presentation and at time of recruitment) * Brain imaging findings on presentation (if applicable) * Chest tube / pigtail details (size, insertion site, duration of placement). * Spirometry testing including forced vital capacity (FVC) and forced expiratory volume (FEV1) at time of enrolment of study Additional information to be collected following hospital stay: * Analgesic use including dose of opioids, use of regional anesthesia techniques, and adjunct analgesic medications while in hospital * Length of hospital stay * Presence and duration of mechanical ventilation * Number of surgeries Follow ups: 1 (± 3 days) and 3 months (± 1 week) via telephone * Pain assessment using the numerical rating scale at rest and with deep inspiration * Self-Report Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) for neuropathic pain * EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L) for health related quality of life * Patient-Reported Outcomes Measurement Information System (PROMIS) sleep disturbance 6a for sleep * Medication use (analgesics, neuropathic pain medications) * Neurologic assessment at discharge (GCS, diagnosis of traumatic brain injury) * Brain imaging findings on presentation (if applicable) Patients who are found to have intercostal neuralgia at 3 month follow up assessment can be referred to the pain clinic and choose to be sent for formal ultrasound to identify and characterize findings to indicate the presence of neuroma (a non-cancerous tumor or growth of nerve tissue), degree of scarring, or any other pain generating causes, if agreed. Participants' preferences regarding the disclosure of neuroma, including their right to know or not to know, will be respected (as described in the consent form).

Interventions

Insertion of chest tube

Sponsors

Sunnybrook Health Sciences Centre
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults (≥18 years) with traumatic rib fractures requiring chest tube insertion * Chest tube or pigtail insertion performed during their initial hospitalization for trauma

Exclusion criteria

* Patients with spinal cord injury * Inability to complete follow-up assessments (e.g., language barriers, lack of telephone access)

Design outcomes

Primary

MeasureTime frameDescription
Incidence of intercostal neuralgia1 and 3 monthsTo determine the incidence of intercostal neuralgia in patients undergoing chest tube insertion after traumatic rib fractures. Presence of neuropathic pain to be assessed using S-LANSS (score of 12 or more suggests pain of predominantly neuropathic origin)

Secondary

MeasureTime frameDescription
Assess the impact of intercostal neuralgia on quality of life and functional outcomes1 and 3 monthsAssess the impact of intercostal neuralgia on quality of life using EQ-5D-5L (assesses 5 dimensions, with 1 indicating 'no problems' and 5 indicating 'extreme problems')
Assess the impact of intercostal neuralgia on medication use1 and 3 monthsDetermine the impact of intercostal neuralgia on medication use including opioids and anti-neuropathic medications by collection and assessment of quantity of medications taken for pain relief related to intercostal neuralgia.

Countries

Canada

Contacts

CONTACTHoward Meng, MD
howard.meng@sunnybrook.ca416-480-4864
CONTACTLilia Kauistov, PhD
lilia.kaustov@sunnybrook.ca416-480-4864

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 16, 2026